Tech Company Financing Transactions

Trius Therapeutics Funding Round

Sofinnova Ventures, InterWest Partners and Prism VentureWorks participated in a $20 million Series A capital raise for Trius Therapeutics. The financing round closed on 2/27/2007.

Transaction Overview

Company Information

Company Status

Acquired or Merged

Industry

Biopharmaceutical

Mailing Address

6310 Nancy Ridge Drive 105
San Diego, CA 92121
USA

Phone

(858) 452-0370

Website

www.triusrx.com

Email Address

[email protected]

Overview

Trius Therapeutics is discovering and developing innovative antibacterial drugs for thetreatment of life-threatening infections. The company's lead product candidate, TR-701 isa novel oral and IV oxazolidinone antibiotic with potent activity against Gram positivebacterial pathogens.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Jeffrey Stein

        

Chief Financial Officer

John Schmid

        

Chief Medical Officer

Philippe Prokocimer

        

Chief Scientific Officer

John Finn

        

VP - Bus. Development

Neil Abdollahian

        

VP - Regulatory Affairs

Karen Potts

        

Browse more venture capital transactions:

Prev: 2/27/2007: Spadac venture capital transaction
Next: 2/27/2007: MATE Intelligent Video venture capital transaction

Share this article

About Our Venture Capital Transactions Database

Our team works diligently to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary